Royal Bank of Canada Has $1.60 Million Stock Holdings in Dianthus Therapeutics, Inc. $DNTH

Royal Bank of Canada boosted its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 847.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 19,064 shares of the company’s stock after acquiring an additional 17,052 shares during the period. Royal Bank of Canada’s holdings in Dianthus Therapeutics were worth $1,601,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Dianthus Therapeutics by 24.7% in the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares during the last quarter. UBS Group AG raised its stake in shares of Dianthus Therapeutics by 342.6% during the fourth quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after buying an additional 469,547 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Dianthus Therapeutics by 1,275.3% during the fourth quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock worth $19,606,000 after buying an additional 441,156 shares during the last quarter. SummitTX Capital L.P. raised its stake in shares of Dianthus Therapeutics by 13.8% during the first quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock worth $8,396,000 after buying an additional 12,118 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Dianthus Therapeutics by 154.9% in the first quarter. The Manufacturers Life Insurance Company now owns 65,238 shares of the company’s stock valued at $5,475,000 after buying an additional 39,640 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DNTH has been the topic of a number of recent research reports. Guggenheim reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Truist Financial increased their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. HC Wainwright raised their price target on Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $131.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $124.27.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $113.70 on Thursday. The company’s 50 day simple moving average is $99.51 and its 200 day simple moving average is $84.41. Dianthus Therapeutics, Inc. has a fifty-two week low of $22.06 and a fifty-two week high of $117.88. The firm has a market capitalization of $6.22 billion, a price-to-earnings ratio of -27.40 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. As a group, analysts predict that Dianthus Therapeutics, Inc. will post -3.83 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Anne Mcgeorge sold 7,750 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $109.01, for a total transaction of $844,827.50. Following the sale, the director owned 1,250 shares of the company’s stock, valued at approximately $136,262.50. This trade represents a 86.11% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Marino Garcia sold 166,000 shares of Dianthus Therapeutics stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $108.11, for a total value of $17,946,260.00. Following the transaction, the chief executive officer owned 65,292 shares in the company, valued at approximately $7,058,718.12. This represents a 71.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 287,084 shares of company stock worth $29,615,923 over the last ninety days. Insiders own 3.02% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.